Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)
It is an open labelled, randomized, multi-center phase III clinical trail.A total of 1108
patients with resected stage IB to stage IIIA non-small cell lung cancer will either ether
the group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus
cisplatin randomly. The primary end point was overall survival; principal secondary end
points were recurrence-free survival and the toxicity and safety of the regimens.The major
inclusive criteria are pathological confirmed non-small cell lung cancer after complete
resection and can tolerate chemotherapy safely.The tissue and blood samples will be banked
for further investigation. All of the enrolled patients will be followed up until death or
over 5 years.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
five year
Yes
Jie He, M.D. & Ph.D.
Study Chair
Cancer Hospital ,Chinese Academy of Medical Sciences
China: Ministry of Health
2006 BAI02A02[1]-01
NCT00576914
June 2007
June 2012
Name | Location |
---|